Summary of Product Characteristics Updated 19-Nov-2026 | Aristo Pharma Limited
Nitrofurantoin 25mg/5ml Oral Suspension
Each 5 ml contains 25 mg of nitrofurantoin (as monohydrate).
Excipients with known effect:
Glycerol 525.0mg per 5ml
Methyl parahydroxybenzoate 6.0mg per 5 ml
Ethyl parahydroxybenzoate 2.5mg per 5 ml
For the full list of excipients, see section 6.1.
Oral Suspension.
A yellow suspension with characteristic apricot odour.
For the treatment of and prophylaxis against acute or recurrent, uncomplicated lower urinary tract infections or pyelitis either spontaneous or following surgical procedures. It is indicated in adults and children over 3 months of age.
Nitrofurantoin Oral Suspension is specifically indicated for the treatment of infections when due to susceptible strains of Escherichia coli, Enterococci, Staphylococci, Citrobacter, Klebsiella and Enterobacter.
Posology
Adults
Acute Uncomplicated Urinary Tract Infections: 50mg four times daily for seven days
Severe Chronic Recurrence: 100mg four times a day for seven days
Long Term Suppression: 50mg - 100mg once a day.
Prophylaxis: 50mg four times daily for the duration of procedure and 3 days thereafter.
Paediatric population
Children and Infants over three months of age
Acute Urinary Tract Infections: 3mg/kg/day in four divided doses for seven days.
Suppressive: 1mg/kg, once a day.
Elderly
Provided there is no significant renal impairment, in which Nitrofurantoin is contraindicated, the dosage should be that for any normal adult. See precaution and risks to elderly patients associated with long term therapy (see section 4.8).
Renal impairment
Nitrofurantoin is contraindicated in patients with renal dysfunction and in patients with an eGFR of less than 45 ml/minute (see sections 4.3 & 4.4).
Method of administration
For oral use.
The oral suspension must be shaken well for at least 5 seconds before use.
This medicine should always be taken with food or milk. Taking Nitrofurantoin Oral Suspension with a meal improves absorption and is important for optimal efficacy.
• Hypersensitivity to the active substance, other nitrofurans or to any of the excipients listed in section 6.1.
• Patients suffering from renal dysfunction with an eGFR below 45 ml/minute.
• G6PD deficiency (see also section 4.6).
• Acute porphyria.
• In infants under three months of age as well as pregnant patients at term (during labour and delivery) because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn infant due to immature erythrocyte enzyme systems.
Nitrofurantoin is not effective for the treatment of parenchymal infections of unilaterally non-functioning kidney. A surgical cause for infection should be excluded in recurrent or severe cases.
Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower urinary tract infection in individual cases with an eGFR between 30-44 ml/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.
Since pre-existing conditions may mask adverse reactions, Nitrofurantoin should be used with caution in patients with pulmonary disease, hepatic dysfunction, neurological disorders, and allergic diathesis.
Peripheral neuropathy and susceptibility to peripheral neuropathy, which may become severe or irreversible, has occurred and may be life threatening. Therefore, treatment should be stopped at the first signs of neural involvement (paraesthesia).
Nitrofurantoin should be used with caution in patients with anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions and Vitamin B (particularly folate) deficiency.
Pulmonary adverse reactions
Acute, subacute and chronic pulmonary reactions have been observed in patients treated with nitrofurantoin. If these reactions occur, nitrofurantoin should be discontinued immediately. Signs of pulmonary damage include difficulty and or pain when breathing, shortness of breath and coughing up blood or mucus.
Chronic pulmonary reactions
Chronic pulmonary reactions (including pulmonary fibrosis and diffuse interstitial pneumonitis) can develop insidiously and can often occur in elderly patients. Close monitoring of the lung disease of patients receiving long-term therapy is indicated (especially in the elderly).
Acute pulmonary reactions
Pulmonary reactions may be acute and usually occur within the first week of treatment. Increased vigilance for respiratory symptoms in patients who have just started therapy is warranted (especially in the elderly).
Patients should be monitored closely for signs of hepatitis (particularly in long terms use).
Urine may be coloured yellow or brown after taking Nitrofurantoin. Patients on Nitrofurantoin are susceptible to false positive urinary glucose (if tested for reducing substances).
Nitrofurantoin should be discontinued at any sign of haemolysis in those with suspected glucose-6-phosphate dehydrogenase deficiency.
Hepatotoxicity
Hepatic reactions, including hepatitis, autoimmune hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been reported. The onset of chronic active hepatitis may be insidious, and patients should be monitored periodically for changes in biochemical tests that would indicate liver injury. If hepatitis occurs, the drug should be withdrawn immediately and appropriate measures should be taken.
Discontinue treatment with Nitrofurantoin if otherwise unexplained pulmonary, hepatic, haematological or neurological syndromes occur.
Excipient warnings:
This medicine contains 525.0mg glycerol in each 5ml. May cause headache, stomach upset and diarrhoea.
This medicine contains 6.0mg methyl parahydroxybenzoate in each 5ml. May cause allergic reactions (possibly delayed).
This medicine contains 2.5mg ethyl parahydroxybenzoate in each 5ml. May cause allergic reactions (possibly delayed).
This medicine contains less than 1.5mg propylene glycol in each 5ml.
This medicine contains less than 1mmol sodium (23mg) per 5ml dose, that is to say essentially 'sodium-free'.
1. Increased absorption with food or agents delaying gastric emptying.
2. Decreased absorption with magnesium trisilicate.
3. Decreased renal excretion of Nitrofurantoin by probenecid and sulfinpyrazone.
4. Decreased anti-bacterial activity by carbonic anhydrase inhibitors and urine alkalisation.
5. Anti-bacterial antagonism by quinolone anti-infectives.
6. Interference with some tests for glucose in urine.
7. As Nitrofurantoin belongs to the group of Antibacterials it will have the following resulting interactions:
Typhoid Vaccine (oral): Antibacterials inactivate oral typhoid vaccine.
Pregnancy
Animal studies with Nitrofurantoin have shown no teratogenic effects, however a study in rats has shown reproductive toxicity (see section 5.3). Nitrofurantoin has been in extensive clinical use since 1952 and its suitability in human pregnancy has been well documented. However, as with all other drugs, the maternal side effects may adversely affect the course of pregnancy. The drug should be used at the lowest dose as appropriate for the specific indication, only after careful assessment. Nitrofurantoin is however contraindicated in infants under three months of age and in pregnant women during labour and delivery, because of the possible risk of haemolysis of the infants' immature red cells.
Breast-feeding
Breast feeding an infant known or suspected to have an erythrocyte enzyme deficiency (including G6PD deficiency), must be temporarily avoided, since Nitrofurantoin is detected in trace amounts in breast milk.
Fertility
No data available.
Nitrofurantoin may cause dizziness and drowsiness. Patients should be advised not to drive or operate machinery if affected in this way until such symptoms go away.
A tabulated list of undesirable effects is outlined below:
The undesirable effects are listed according to organ systems and following frequencies:
Rare (≥1/10,000 to <1/1,000)
Not known (cannot be estimated from the available data)
| System organ class | Frequency | Adverse reaction |
| Infections and infestations | Not known | Superinfections by fungi or resistant organisms such as Pseudomonas. However, these are limited to the genitourinary tract |
| Blood and lymphatic system disorders | Rare | Aplastic anaemia |
| Not known | Agranulocytosis, leucopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia, glucose¬6-phosphatedehydrogenase deficiency anaemia, megaloblastic anaemia and eosinophilia | |
| Immune system disorders | Not known | Anaphylaxis, angioneurotic oedema, cutaneous vasculitis and allergic skin reactions |
| Psychiatric disorders | Not known | Psychotic reactions, depression, euphoria, confusion |
| Nervous system disorders | Not known | Benign intracranial hypertension, peripheral neuropathy including optic neuritis (sensory as well as motor involvement), nystagmus, vertigo, dizziness, headache and drowsiness. |
| Cardiac disorders | Rare | Collapse and cyanosis |
| Respiratory, thoracic and mediastinal disorders | Not known | Pulmonary fibrosis; possible association with lupus erythematous-like syndrome, acute pulmonary reactions*, subacute pulmonary reactions*, chronic pulmonary reactions*, cough, dyspnoea |
| Gastrointestinal disorders | Not known | Sialoadenitis, pancreatitis, anorexia, emesis, abdominal pain, diarrhoea and nausea |
| Hepatobiliary disorders | Not known | Chronic active hepatitis**, hepatic necrosis, autoimmune hepatitis, cholestatic jaundice |
| Skin and subcutaneous tissue disorders | Not known | Lupus-like syndrome associated with pulmonary reaction. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome), cutaneous vasculitis, exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome), maculopapular, erythematous or eczematous eruptions, urticaria, rash, pruritis and Transient alopecia |
| Renal and urinary disorders | Not known | Interstitial nephritis, yellow or brown discolouration of urine, |
| General disorders and administration site conditions | Not known | Asthenia, fever, chills, drug fever and arthralgia |
| Investigations | Not known | False positive urinary glucose |
*Acute pulmonary reactions usually occur within the first week of treatment and are reversible with cessation of therapy. Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnoea, pulmonary infiltration with consolidation or pleural effusion on chest x-ray, and eosinophilia. In subacute pulmonary reactions, fever and eosinophilia occur less often than in the acute form. Chronic pulmonary reactions occur rarely in patients who have received continuous therapy for six months or longer and are more common in elderly patients. Changes in ECG have occurred, associated with pulmonary reactions.
**Fatal events have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Symptoms and signs of overdose include gastric irritation, nausea and vomiting.
Management
There is no known specific antidote. However, Nitrofurantoin can be haemodialysed in cases of recent ingestion. Standard treatment is by induction of emesis or by gastric lavage. Monitoring of full blood count, liver function, and pulmonary function tests are recommended. A high fluid intake should be maintained to promote urinary excretion of the drug.
Pharmacotherapeutic group: Antibacterials for systemic use, Nitrofuran derivatives, ATC code: J01XE01
Mechanism of action
Nitrofurantoin is a broad-spectrum antibacterial agent, active against the majority of urinary pathogens. The wide range of organisms sensitive to the bactericidal activity include:
Escherichia coli
Enterococcus Faecalis
Klebsiella Species
Enterobacter Species
Staphylococcus Species, e.g. S. Aureus, S. Saprophyticus, S. Epidermidis
Citrobacter Species
Clinically most common urinary pathogens are sensitive to Nitrofurantoin. Most strains of Proteus and Serratia are resistant. All pseudomonas strains are resistant.
Absorption
Orally administered Nitrofurantoin is readily absorbed in the upper gastrointestinal tract and is rapidly excreted in the urine. Blood concentrations at therapeutic dosages are usually low.
Elimination
Maximum urinary excretion usually occurs 2-4 hours after administration of Nitrofurantoin. Urinary drug dose recoveries of about 40-45% are obtained. It has an elimination half-life of about 30 minutes.
The available genotoxicity data indicate that nitrofurantoin is a mutagen. Two-year carcinogenicity studies in rats and mice reported carcinogenic effects. The relevance of the genotoxic and carcinogenic potential of nitrofurantoin to human is unknown. Extensive clinical use of Nitrofurantoin over 65 years has not found any conclusive evidence for carcinogenic effects at therapeutic dosages.
In rats, at high doses a temporary halt in spermatogenesis was observed. No decreased fertility was observed in animal studies.
Glycerol (E422)
Carbopol (Carbomer) 974P
Tween 20 (Polysorbate 20)
Saccharin Sodium (E954)
Sucralose
Methyl Parahydroxybenzoate (E218)
Ethyl Parahydroxybenzoate (E214)
Apricot flavour (containing propylene glycol, E1520)
Sodium Hydroxide (E524)
Hydrochloric acid (E507)
Purified water
Not applicable.
24 months (unopened)
After first opening: 30 days
Store in the original container in order to protect from light and moisture.
Do not store above 30°C. Do not freeze.
This suspension is supplied in 300 ml Type III amber glass bottles sealed with a polypropylene, child-resistant, tamper evident cap. A 5 ml HDPE/polypropylene dosing syringe with 0.1 ml graduations is included in the carton with a syringe adaptor.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Aristo Pharma GmbH
Wallenroder Strasse 8-10
13435 Berlin
Germany
PL 40546/0256
13/05/2026
13/05/2026
The North Suite, Avro House, 49 Lancaster Way Business Park, Ely, Cambridgeshire, CB6 3NW, UK
01483 920754
+44 (0)1353 887 100
+44 (0)1353 887 100
www.aristo-pharma.co.uk